Abstract

US Physical Therapy will report results on August 5, 2026 Post Market, and consensus tracking points to mid–single-digit margin stability with double‑digit revenue and EPS growth expectations relative to last year.

Market Forecast

Forecasts for the current quarter indicate revenue of 211.31 million US dollars, implying year‑over‑year growth of 11.45%, and adjusted EPS of 0.84, implying year‑over‑year growth of 17.95%; EBIT is projected at 24.17 million US dollars, a 13.37% increase year over year. Forecast data for gross profit margin and net profit margin have not been provided, so they are not included here.

The company’s core operating engine remains patient services, where volume and rate trends are expected to sustain mid‑to‑high single‑digit organic traction, supplemented by clinic additions and integration benefits from recent acquisitions. Within the portfolio, patient services appears to be the most promising near‑term growth lever, supported by last quarter’s segment revenue of 164.33 million US dollars; segment‑level year‑over‑year growth was not disclosed, but management initiatives and consensus modeling imply growth consistent with the corporate top line.

Last Quarter Review

In the prior quarter, US Physical Therapy posted revenue of 198.29 million US dollars, up 7.89% year over year, with a gross profit margin of 19.53%, GAAP net profit attributable to shareholders of 5.04 million US dollars, a net profit margin of 2.57%, and adjusted EPS of 0.46, representing a year‑over‑year change of -4.17%. EBIT for the quarter was 15.73 million US dollars, essentially flat year over year, reflecting operating expense pressures offset by steady volumes.

Business performance was marked by disciplined pricing and throughput, with operational throughput and clinic density supporting steady revenue per clinic despite ongoing cost inflation. By segment, patient services contributed 164.33 million US dollars, while other services delivered 33.96 million US dollars; the company did not provide segment‑level year‑over‑year growth metrics for the quarter.

Current Quarter Outlook (with major analytical insights)

Patient services: visit momentum, pricing cadence, and throughput

For this quarter, patient services is positioned to carry the revenue trajectory, with forecasts implying an 11.45% year‑over‑year revenue increase at the consolidated level. The drivers to watch are visit growth and revenue per visit, where cadence is influenced by physician referral trends, seasonal activity, and contract pricing that typically resets over the course of the calendar year. The mix of commercial and government payers can modestly skew realized rates, but recent quarters suggest resilience in average reimbursement that complements steady patient flows. On the operations side, therapist productivity and schedule utilization underpin unit economics; centers that maintain stable clinician staffing and front‑office support usually outperform on same‑clinic growth, and the spring‑to‑summer period often supports higher throughput. The reported gross margin of 19.53% last quarter provides a baseline; maintaining or improving this in the current quarter will likely hinge on clinician labor costs and overtime control, which industry‑wide remain sensitive to wage inflation and market‑by‑market competition for licensed therapists. From a flow‑through perspective, incremental revenue from higher visit counts tends to drop at a better‑than‑proportional rate when fixed clinic overhead is fully utilized, potentially aiding EBIT growth relative to revenue.

Other services and ancillary lines: incremental leverage, smaller base

Other services, at 33.96 million US dollars last quarter, represent a smaller but strategically useful contributor, typically associated with employer‑direct programs and ancillary offerings around the core physical therapy clinics. While segment‑level growth data has not been disclosed, this line can provide incremental margin leverage when deployed across the existing clinic footprint, because shared administrative infrastructure tends to be already in place. The near‑term outlook depends on contract renewals and cross‑selling into the clinic base; where corporate and payer partners adopt standardized injury‑prevention or return‑to‑work programs, utilization can scale rapidly from a relatively low starting point. Given the base size, even modest contract wins can produce visibly higher percentage growth, although the absolute dollar contribution remains secondary to patient services this quarter. Execution risk primarily lies in onboarding timelines and customer adoption, which can introduce quarter‑to‑quarter variability without necessarily signaling a change in medium‑term momentum.

Stock price swing factors: earnings quality, margin prints, and M&A cadence

Share performance around the print is likely to respond to the quality of earnings relative to consensus, particularly the interplay between revenue growth and margins. With last quarter’s net margin at 2.57% and gross margin at 19.53%, investors will scrutinize whether cost controls and clinician staffing stability allow EBIT to scale in line with or ahead of revenue; model expectations call for EBIT of 24.17 million US dollars, implying 13.37% growth year over year, which would mark a positive inflection versus the largely flat outcome last quarter. Adjusted EPS is forecast at 0.84, up 17.95% year over year, and any deviation there will likely move the stock, with a higher‑quality beat being one that pairs revenue upside with stable or expanding margins rather than one‑off items. Beyond quarterly margins, the pace and strategic fit of acquisitions remain a theme: the company announced that it acquired a 67% interest in a 12‑clinic practice effective July 1, 2026, expanding its footprint to 45 states, which, while not impacting the current quarter’s reported results, can influence sentiment around the back‑half revenue and margin trajectory. Integration progress, clinician retention in newly acquired clinics, and any early read on visit volumes in those clinics will be relevant datapoints raised during management commentary and Q&A.

Analyst Opinions

The balance of institutional commentary over the past six months is bullish, with positive views meaningfully outnumbering negative ones; across the tracked opinions, bullish calls constitute the clear majority. Notably, J.P. Morgan has reiterated a Buy rating twice during the period, with price targets updated around 90 to 100 US dollars, framing the setup as favorable into the mid‑year print given improving visibility into growth and margin stability. In parallel, Barrington Research maintained an Outperform rating while revising its price target to 90 US dollars, emphasizing that the company’s operating model remains structurally sound despite a softer first‑quarter comparison and that the outlook is supported by organic growth plus acquisition contributions.

In synthesizing these perspectives, the majority camp is anchoring on three points that align with this quarter’s setup. First, revenue growth durability: consensus revenue of 211.31 million US dollars suggests mid‑teens growth on better volumes and pricing, which analysts see as achievable given the sequential pickup in throughput from early‑year seasonality and continued clinic productivity. Second, operating leverage: with EBIT expected to rise by 13.37% year over year, the bullish case assumes cost normalization in clinician labor and better capacity utilization, which together can support incremental margin improvement even without aggressive pricing changes. Third, external growth: the July acquisition of a 12‑clinic practice adds to the back‑half pipeline and demonstrates continued access to high‑quality partners; while not in the current quarter’s numbers, it informs models for the remainder of the year and reinforces confidence in revenue compounding beyond organic visit growth.

These institutions also highlight a few watch‑items that are more about execution than thesis‑breaking risks. Segment‑level disclosure on growth is limited, so analysts will look for qualitative color on patient services momentum by geography and payer mix, especially where authorization and denial trends can affect realized volumes. Additionally, while adjusted EPS of 0.84 is the headline focus, the composition behind that figure—specifically the balance between operating income and any non‑operating items—will be a determinant of whether any beat is considered high‑quality. Given the positive skew in published ratings, the majority view is that the risk‑reward remains favorable into the announcement, contingent on revenue landing around 211.31 million US dollars and the company demonstrating clear progress on leverage from its 19.53% gross margin baseline and 2.57% net margin footprint in the prior quarter.

To frame expectations succinctly, the bullish constituency anticipates a report characterized by solid top‑line growth, a return to year‑over‑year EPS expansion, and a forward narrative supported by the recent clinic acquisition, all of which could underpin constructive revisions if execution meets or exceeds the current forecasts. Conversely, a miss tied to margin compression rather than transient items would be the primary concern flagged by the same analysts, but this remains a risk rather than a base case in their published views.